Last reviewed · How we verify
Bifonazole spray twice daily
Bifonazole is an antifungal agent that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.
Bifonazole is an antifungal agent that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. Used for Cutaneous candidiasis, Dermatophytosis.
At a glance
| Generic name | Bifonazole spray twice daily |
|---|---|
| Sponsor | Bayer |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Bifonazole is a triazole antifungal that binds to the fungal enzyme lanosterol 14α-demethylase, preventing the conversion of lanosterol to ergosterol. This disrupts the integrity of the fungal cell membrane, ultimately leading to cell death. Bifonazole is effective against a range of fungal pathogens, including dermatophytes and yeasts.
Approved indications
- Cutaneous candidiasis
- Dermatophytosis
Common side effects
- Skin irritation
- Allergic reactions
- Headache
Key clinical trials
- Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bifonazole spray twice daily CI brief — competitive landscape report
- Bifonazole spray twice daily updates RSS · CI watch RSS
- Bayer portfolio CI